Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 10, 2011, Pages 1043-1049

  Hsiao, Fei Yuan ^a   Mullins, C Daniel ^b   Wen, Yu Wen ^c   Huang, Weng Foung ^d   Chen, Pei Fen ^e   Tsai, Yi Wen ^d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Acute coronary syndrome; Adverse cardiovascular outcomes; Clopidogrel; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE OUTCOME; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; FEMALE; HOSPITAL READMISSION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; DRUG INTERACTIONS; FEMALE; HERB-DRUG INTERACTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 80053276727     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2202     Document Type: Article

References (34)

1. Steinhubl SR, Berger PB, Mann JT, III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.
2. King SB, III, Smith SC, Jr., Hirshfeld JW, Jr., et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.
3. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726.
4. Kwok CS, Nijjar RS, Loke YK.Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. Drug Saf 2011; 34: 47-57.
5. Khalique SC, Lai AC. Drug interaction between clopidogrel and proton pump inhibitor. Cardiol in Review 2009; 17: 198-200.
6. Last EJ, Sheehan AH. Review of recent evidence: potential interaction between clopidogrel and proton pump inhibitors. Am J Health Syst Pharm 2009; 66: 2117-2122.
7. Liu TJ, Jackevicius CA. Drug interaction between clopidogrel and proton pump inhibitors. Pharmacotherapy 2010; 30: 275-289.
8. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel.N Engl J Med 2009; 360: 354-362.
9. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
10. Gurbel PA, Lau WC, Tantry US. Omeprazole- A possible new candidate influencing the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 51: 261-263.
11. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718.
12. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
13. Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010; 170: 704-710.
14. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trial. Lancet 2009; 374: 989-997.
15. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med 2010; 363: 1909-1917.
16. Dunn SP, Macaulay TE, Brennan DM, et al. Abstract 3999: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008; 118: S815.
17. Kwok CS, Loke YK. Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31: 810-823.
18. Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-2329.
19. Bureau of National Health Insurance. National Health Insurance in Taiwan, 2007. Available at: (accessed 19 March 2010).
20. Rossini R, Capodanno D, Musumeci G, et al. Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. Coron Artery Dis 2011; 22: 199-205.
21. Harjai KJ, Shenoy C, Orshaw P, et al. Clinical Outcomes in Patients With the Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention: An Analysis From the Guthrie Health Off-Label Stent (GHOST) Investigators. Circ Cardiovasc Interv 2011; 4: 162-170.
22. Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol 2011; 107: 871-878.
23. Yusurf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
24. Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 2009; 120: 2310-2312.
25. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-827.
26. Ma TK, Lam YY, Tan VP, et al. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacol Ther 2010; 125: 249-259.
27. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54: 1149-1153.
28. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
29. Yun KH, Rhee SJ, Park HY, et al. Effects of omeprazole on the antiplatelet activity of clopidogrel. Int Heart J 2010; 51: 13-16.
30. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148e1-148e5.
31. Fontes-Carvalho R, Albuquerque A, Araújo C, et al. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol 2011; 23: 396-404.
32. Rossini R, Capodanno D, Lettieri C, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011; 107: 186-194.
33. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 59-64.
34. Tseng PH, Lee YC, Chiu HM, et al. A comparative study of proton-pump inhibitor tests for Chinese reflux patients in relation to the CYP2C19 genotypes. J Clin Gastroenterol 2009; 43: 920-925.